Acetylsalicylic Acid

證據等級: L5

預測適應症: 10 個

Acetylsalicylic Acid: From Pain and Cardiovascular Management to Migraine with Brainstem Aura

One-Sentence Summary

Acetylsalicylic acid (aspirin) is one of medicine’s oldest and most versatile agents, widely used for analgesia, antipyresis, and cardiovascular event prevention through its COX-inhibiting and antiplatelet mechanisms. The TxGNN model predicts it may be effective for migraine with brainstem aura — a rare migraine subtype formerly known as basilar migraine — with no registered clinical trials and 19 publications currently exploring this direction. While biological plausibility exists through prostaglandin and TXA2 suppression, the brainstem aura phenotype carries unique vascular considerations that require prospective validation before clinical application.

Quick Overview

Item	Content
Original Indication	No ARTG-registered indication data returned in this dataset; aspirin is a well-established analgesic, antipyretic, anti-inflammatory, and antiplatelet agent
Predicted New Indication	Migraine with brainstem aura
TxGNN Prediction Score	99.94%
Evidence Level	L3
Australia Market Status	Not listed in current dataset (ARTG query returned 0 results — direct TGA verification recommended)
Number of ARTG Entries	0 (dataset query; see note below)
Recommended Decision	Research Question

Important note on Australian market status: The regulatory query in this Evidence Pack returned no ARTG entries for acetylsalicylic acid. This is inconsistent with aspirin’s well-known widespread availability in Australia as both an over-the-counter and prescription medicine. The absence of entries reflects a data source limitation in this dataset, not the drug’s actual market status. Clinicians should verify directly with the TGA ARTG database.

Why is This Prediction Reasonable?

Although formal MOA data was not retrieved in this Evidence Pack, aspirin’s pharmacology is among the most thoroughly characterised in all of medicine. Aspirin irreversibly acetylates cyclo-oxygenase-1 (COX-1) and COX-2 enzymes, suppressing downstream synthesis of prostaglandins and thromboxane A2 (TXA2). This dual action underpins its analgesic, anti-inflammatory, antipyretic, and antiplatelet effects. At low doses, COX-1 inhibition in platelets predominates, effectively blocking TXA2-mediated platelet aggregation and vasoconstriction for the platelet’s lifespan.

Migraine with brainstem aura (MBrA, formerly “basilar migraine”) is characterised by neurological aura symptoms arising from brainstem or bilateral occipital lobe structures — including diplopia, dysarthria, tinnitus, ataxia, decreased consciousness, and bilateral sensory disturbances — preceding the headache phase. The accepted mechanism involves cortical spreading depression (CSD) extending into brainstem territories, with subsequent trigeminovascular activation and neurogenic inflammation mediated partly by prostaglandins and platelet-derived TXA2. Aspirin’s suppression of both prostaglandin-mediated neuroinflammation and TXA2-driven vasoconstriction provides a mechanistically coherent rationale for potential benefit.

A 2014 retrospective study (PMID 25729594) specifically evaluated low-dose aspirin as prophylactic treatment in 95 patients with migraine with aura (per ICHD-II criteria), showing meaningful reductions in attack frequency. A 2025 systematic review (PMID 39989443) further examined antithrombotic drugs — including aspirin — as migraine preventive therapy. However, a critical caveat applies to the brainstem aura subtype: patients with MBrA were historically excluded from clinical trials of vasoconstrictive acute therapies (triptans, ergotamines) due to concerns about basilar artery stroke risk. Whether antiplatelet therapy with aspirin conveys benefit or poses additional risk in this particular subtype remains an open research question requiring dedicated prospective study.

Clinical Trial Evidence

Currently no registered clinical trials for acetylsalicylic acid specifically in migraine with brainstem aura.

The absence of dedicated trials is clinically significant. Broader clinical trial evidence supports aspirin in acute migraine with or without aura (e.g., PMID 10448545 — IV lysine acetylsalicylate vs sumatriptan), but no trial has prospectively targeted the brainstem aura subtype as a primary endpoint. This gap is a key factor in the L3 evidence classification.

Literature Evidence

PMID	Year	Study Type	Journal	Key Findings
39989443	2025	Systematic Review	Headache	Evaluates antithrombotic drugs (including aspirin) as migraine preventive therapy; reviews biological plausibility of antiplatelet approaches across migraine subtypes
25600718	2015	Evidence Assessment (Systematic)	Headache	American Headache Society updated evidence review of acute migraine pharmacotherapies; includes aspirin as an established acute treatment option with demonstrated efficacy
25729594	2014	Retrospective Study	Current Health Sciences Journal	203 migraine-with-aura patients; 95 treated with low-dose ASA showed reduced attack frequency; most directly relevant evidence for aspirin prophylaxis in the aura-migraine spectrum
10448545	1999	Randomised Controlled Trial	Cephalalgia	278-patient multicentre RCT; IV lysine acetylsalicylate (equivalent to 1g ASA) vs subcutaneous sumatriptan vs placebo for acute migraine with or without aura; ASA demonstrated significant acute efficacy
34384631	2021	Review	Revue neurologique	Comprehensive review of migraine with aura pathophysiology; covers cortical spreading depression mechanism and its pharmacological implications
30291554	2018	Review	Current Pain and Headache Reports	Pathophysiological and clinical differences between migraine with and without aura; informs treatment selection and risk stratification relevant to ASA use
9556832	1998	Review	Schweizerische medizinische Wochenschrift	Reviews migraine treatment mechanisms; notes group studies do not show superiority of ergotamines or sumatriptan over simple analgesics including ASA, particularly with a prokinetic agent
35006660	2022	Guideline Review	FP Essentials	AHA/ASA stroke primary prevention guidelines; provides essential context for aspirin use in patients with migraine with aura who carry an elevated stroke risk
16103551	2005	Observational	Heart (British Cardiac Society)	Clopidogrel (another antiplatelet agent) reduced migraine with aura frequency after transcatheter closure of persistent foramen ovale; supports broader antiplatelet mechanism relevance in aura migraine
34048399	2021	Review	Continuum	Headache in women across the hormonal lifecycle; contextualises migraine with aura treatment considerations including antiplatelet approaches in reproductive-aged women

Australia Market Information

The regulatory dataset query returned no ARTG entries for acetylsalicylic acid. As noted above, this reflects a data source limitation rather than the drug’s actual availability in Australia. Aspirin is widely registered and available in Australia in multiple formulations (immediate-release tablets, enteric-coated tablets, soluble formulations) at various doses for pain, fever, and cardiovascular indications.

Recommended action: Verify current ARTG registration, approved indications, dosage forms, and access the current TGA-approved Product Information (PI) directly at: 👉 https://www.tga.gov.au/resources/artg — search “aspirin” or “acetylsalicylic acid”

Safety Considerations

Please refer to the TGA-approved Product Information (PI) for comprehensive safety information. The safety data fields in this Evidence Pack returned no usable information from the regulatory query.

Clinician advisory — specific to migraine with brainstem aura context: Migraine with brainstem aura was historically classified as a contraindication for triptans and combined oral contraceptives due to concerns about basilar artery territory stroke risk. Prescribers considering aspirin for this population should be aware of:

Gastrointestinal bleeding risk, particularly at higher doses or with prolonged use

The risk–benefit balance of antiplatelet therapy in a population already at elevated cerebrovascular risk

Potential interactions with other anticoagulants or NSAIDs

The need for individualised patient-level risk stratification before initiating therapy outside approved indications

Conclusion and Next Steps

Decision: Research Question (Hold)

Rationale: The TxGNN model assigns a very high confidence score (99.94%), and mechanistic plausibility for aspirin in migraine with brainstem aura is grounded in well-established COX/TXA2 pharmacology. However, current evidence sits at L3 — relying on observational and retrospective data, with no dedicated prospective RCTs for this specific migraine subtype — and the unique neurological risk profile of brainstem aura patients warrants caution before clinical extrapolation.

To proceed, the following is needed:

Prospective RCT specifically enrolling patients with migraine with brainstem aura (currently no trials registered globally)
A systematic review or meta-analysis specifically examining aspirin prophylaxis in the brainstem aura subtype, separated from broader migraine-with-aura studies
Stroke risk stratification data for antiplatelet use in this population, particularly in women of reproductive age
Retrieval and review of the TGA-approved Product Information for aspirin to confirm approved indications, contraindications, and relevant warnings
MOA data retrieval from DrugBank (currently a data gap) to strengthen mechanistic documentation for regulatory submissions
Verification of current ARTG registration status and available dosage forms via the TGA database

This report is generated from the TxGNN drug repurposing evidence framework and is intended for research and clinical evaluation purposes only. It does not constitute medical advice or a recommendation to prescribe outside approved indications. All clinical decisions should incorporate full assessment of individual patient risk and current TGA-approved Product Information.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.